Beam Therapeutics(BEAM) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort Dosing Completed in Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Initial Clinical Data Expecte ...